Stada Arz and mAbxience to negotiate over adalimumab biosimilar

German drugmaker Stada Arzneimittel (SAZ: GR) and the biotech specialist mAbxience have agreed to negotiate over the in-licensing of an adalimumab (Humira) biosimilar.

The letter of intent stipulates that the two negotiating parties will come to a decision within the next six months. The original product, AbbVie’s (NYSE: ABBV) Humira,is the world's top-selling biopharmaceutical with a sales volume in 2013 of around $10.66 billion in 2013.

With these negotiations, Stada continues its longstanding strategy of targeted in-licensing of selected biosimilars; a strategy with which the group is continuously expanding its portfolio of quality products at comparably favorable conditions.